The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach
Total Hip Arthroplasty, Postoperative Blood Loss
About this trial
This is an interventional prevention trial for Total Hip Arthroplasty focused on measuring total hip arthroplasty, tranexamic acid, postoperative blood loss
Eligibility Criteria
Inclusion Criteria:
- patients who will receive a unilateral total hip arthroplasty
Exclusion Criteria:
- coagulopathy
- allergy to tranexamic acid
- preoperative anemia (a hemoglobin value of < 11g/dL in females and < 12g/dL in males)
- fibrinolytic disorders
- a history of arterial or venous thromboembolic disease
- pregnancy
- breastfeeding
- major comorbidities
Sites / Locations
- UZ Pellenberg
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Placebo
Tranexamic acid
The patients who receive placebo form the control group. The results can be compared with the results of the patients who did receive TXA
The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner